UniProt ID | BAG6_HUMAN | |
---|---|---|
UniProt AC | P46379 | |
Protein Name | Large proline-rich protein BAG6 {ECO:0000305} | |
Gene Name | BAG6 {ECO:0000312|HGNC:HGNC:13919} | |
Organism | Homo sapiens (Human). | |
Sequence Length | 1132 | |
Subcellular Localization | Cytoplasm, cytosol . Nucleus . Secreted, exosome . Normally localized in cytosol and nucleus, it can also be released extracellularly, in exosomes, by tumor and myeloid dendritic cells (PubMed:18055229, PubMed:18852879). Cytoplasmic retention is due | |
Protein Description | ATP-independent molecular chaperone preventing the aggregation of misfolded and hydrophobic patches-containing proteins. [PubMed: 21636303 Functions as part of a cytosolic protein quality control complex, the BAG6/BAT3 complex, which maintains these client proteins in a soluble state and participates to their proper delivery to the endoplasmic reticulum or alternatively can promote their sorting to the proteasome where they undergo degradation] | |
Protein Sequence | MEPNDSTSTAVEEPDSLEVLVKTLDSQTRTFIVGAQMNVKEFKEHIAASVSIPSEKQRLIYQGRVLQDDKKLQEYNVGGKVIHLVERAPPQTHLPSGASSGTGSASATHGGGSPPGTRGPGASVHDRNANSYVMVGTFNLPSDGSAVDVHINMEQAPIQSEPRVRLVMAQHMIRDIQTLLSRMETLPYLQCRGGPQPQHSQPPPQPPAVTPEPVALSSQTSEPVESEAPPREPMEAEEVEERAPAQNPELTPGPAPAGPTPAPETNAPNHPSPAEYVEVLQELQRLESRLQPFLQRYYEVLGAAATTDYNNNHEGREEDQRLINLVGESLRLLGNTFVALSDLRCNLACTPPRHLHVVRPMSHYTTPMVLQQAAIPIQINVGTTVTMTGNGTRPPPTPNAEAPPPGPGQASSVAPSSTNVESSAEGAPPPGPAPPPATSHPRVIRISHQSVEPVVMMHMNIQDSGTQPGGVPSAPTGPLGPPGHGQTLGQQVPGFPTAPTRVVIARPTPPQARPSHPGGPPVSGTLQGAGLGTNASLAQMVSGLVGQLLMQPVLVAQGTPGMAPPPAPATASASAGTTNTATTAGPAPGGPAQPPPTPQPSMADLQFSQLLGNLLGPAGPGAGGSGVASPTITVAMPGVPAFLQGMTDFLQATQTAPPPPPPPPPPPPAPEQQTMPPPGSPSGGAGSPGGLGLESLSPEFFTSVVQGVLSSLLGSLGARAGSSESIAAFIQRLSGSSNIFEPGADGALGFFGALLSLLCQNFSMVDVVMLLHGHFQPLQRLQPQLRSFFHQHYLGGQEPTPSNIRMATHTLITGLEEYVRESFSLVQVQPGVDIIRTNLEFLQEQFNSIAAHVLHCTDSGFGARLLELCNQGLFECLALNLHCLGGQQMELAAVINGRIRRMSRGVNPSLVSWLTTMMGLRLQVVLEHMPVGPDAILRYVRRVGDPPQPLPEEPMEVQGAERASPEPQRENASPAPGTTAEEAMSRGPPPAPEGGSRDEQDGASAETEPWAAAVPPEWVPIIQQDIQSQRKVKPQPPLSDAYLSGMPAKRRKTMQGEGPQLLLSEAVSRAAKAAGARPLTSPESLSRDLEAPEVQESYRQQLRSDIQKRLQEDPNYSPQRFPNAQRAFADDP | |
Overview of Protein Modification Sites with Functional and Structural Information | ||
* ASA = Accessible Surface Area
Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
---|---|---|---|---|---|
1 | Acetylation | -------MEPNDSTS -------CCCCCCCC | 63.54 | 19413330 | |
6 | Phosphorylation | --MEPNDSTSTAVEE --CCCCCCCCCCCCC | 30.78 | 20068231 | |
7 | Phosphorylation | -MEPNDSTSTAVEEP -CCCCCCCCCCCCCC | 32.72 | 20068231 | |
8 | Phosphorylation | MEPNDSTSTAVEEPD CCCCCCCCCCCCCCC | 20.51 | 20068231 | |
9 | Phosphorylation | EPNDSTSTAVEEPDS CCCCCCCCCCCCCCC | 34.51 | 20068231 | |
16 | Phosphorylation | TAVEEPDSLEVLVKT CCCCCCCCCHHHHHH | 36.83 | 27251275 | |
22 | Ubiquitination | DSLEVLVKTLDSQTR CCCHHHHHHCCCCCC | 38.93 | 21890473 | |
22 | Ubiquitination | DSLEVLVKTLDSQTR CCCHHHHHHCCCCCC | 38.93 | 21890473 | |
22 | Ubiquitination | DSLEVLVKTLDSQTR CCCHHHHHHCCCCCC | 38.93 | 21890473 | |
22 | Ubiquitination | DSLEVLVKTLDSQTR CCCHHHHHHCCCCCC | 38.93 | 21890473 | |
22 (in isoform 1) | Ubiquitination | - | 38.93 | 21890473 | |
22 (in isoform 2) | Ubiquitination | - | 38.93 | 21890473 | |
22 (in isoform 3) | Ubiquitination | - | 38.93 | 21890473 | |
26 | Phosphorylation | VLVKTLDSQTRTFIV HHHHHCCCCCCEEEE | 36.24 | 17478428 | |
30 | Phosphorylation | TLDSQTRTFIVGAQM HCCCCCCEEEEEEEE | 22.54 | 25690035 | |
40 | Ubiquitination | VGAQMNVKEFKEHIA EEEEECHHHHHHHHH | 53.05 | 21890473 | |
40 | Ubiquitination | VGAQMNVKEFKEHIA EEEEECHHHHHHHHH | 53.05 | 21890473 | |
40 | Ubiquitination | VGAQMNVKEFKEHIA EEEEECHHHHHHHHH | 53.05 | 21890473 | |
40 | Ubiquitination | VGAQMNVKEFKEHIA EEEEECHHHHHHHHH | 53.05 | 21890473 | |
40 (in isoform 1) | Ubiquitination | - | 53.05 | 21890473 | |
40 (in isoform 2) | Ubiquitination | - | 53.05 | 21890473 | |
40 (in isoform 3) | Ubiquitination | - | 53.05 | 21890473 | |
56 | Ubiquitination | SVSIPSEKQRLIYQG HCCCCHHHHHHHEEC | 45.09 | 21890473 | |
56 | Ubiquitination | SVSIPSEKQRLIYQG HCCCCHHHHHHHEEC | 45.09 | 21890473 | |
56 | Ubiquitination | SVSIPSEKQRLIYQG HCCCCHHHHHHHEEC | 45.09 | 21890473 | |
56 | Acetylation | SVSIPSEKQRLIYQG HCCCCHHHHHHHEEC | 45.09 | 20167786 | |
56 | Ubiquitination | SVSIPSEKQRLIYQG HCCCCHHHHHHHEEC | 45.09 | 21890473 | |
56 (in isoform 1) | Ubiquitination | - | 45.09 | 21890473 | |
56 (in isoform 2) | Ubiquitination | - | 45.09 | 21890473 | |
56 (in isoform 3) | Ubiquitination | - | 45.09 | 21890473 | |
70 | 2-Hydroxyisobutyrylation | GRVLQDDKKLQEYNV CEECCCCHHHEEEEC | 64.77 | - | |
70 | Acetylation | GRVLQDDKKLQEYNV CEECCCCHHHEEEEC | 64.77 | 25953088 | |
70 | Ubiquitination | GRVLQDDKKLQEYNV CEECCCCHHHEEEEC | 64.77 | - | |
71 | Ubiquitination | RVLQDDKKLQEYNVG EECCCCHHHEEEECC | 63.50 | - | |
75 | Phosphorylation | DDKKLQEYNVGGKVI CCHHHEEEECCCEEE | 11.37 | 28152594 | |
80 | Ubiquitination | QEYNVGGKVIHLVER EEEECCCEEEEEEEC | 31.89 | 21890473 | |
80 | Ubiquitination | QEYNVGGKVIHLVER EEEECCCEEEEEEEC | 31.89 | 21890473 | |
80 | Ubiquitination | QEYNVGGKVIHLVER EEEECCCEEEEEEEC | 31.89 | 21890473 | |
80 | Ubiquitination | QEYNVGGKVIHLVER EEEECCCEEEEEEEC | 31.89 | 21890473 | |
80 (in isoform 1) | Ubiquitination | - | 31.89 | 21890473 | |
80 (in isoform 2) | Ubiquitination | - | 31.89 | 21890473 | |
80 (in isoform 3) | Ubiquitination | - | 31.89 | 21890473 | |
92 | Phosphorylation | VERAPPQTHLPSGAS EECCCCCCCCCCCCC | 31.02 | 23927012 | |
96 | Phosphorylation | PPQTHLPSGASSGTG CCCCCCCCCCCCCCC | 54.04 | 22167270 | |
99 | Phosphorylation | THLPSGASSGTGSAS CCCCCCCCCCCCCCC | 32.59 | 30266825 | |
100 | Phosphorylation | HLPSGASSGTGSASA CCCCCCCCCCCCCCC | 39.58 | 30266825 | |
102 | Phosphorylation | PSGASSGTGSASATH CCCCCCCCCCCCCCC | 29.88 | 30266825 | |
104 | Phosphorylation | GASSGTGSASATHGG CCCCCCCCCCCCCCC | 20.91 | 22167270 | |
106 | Phosphorylation | SSGTGSASATHGGGS CCCCCCCCCCCCCCC | 35.08 | 29255136 | |
108 | Phosphorylation | GTGSASATHGGGSPP CCCCCCCCCCCCCCC | 20.68 | 22167270 | |
113 | Phosphorylation | SATHGGGSPPGTRGP CCCCCCCCCCCCCCC | 31.06 | 29255136 | |
117 | Phosphorylation | GGGSPPGTRGPGASV CCCCCCCCCCCCCCC | 37.92 | 22167270 | |
123 | Phosphorylation | GTRGPGASVHDRNAN CCCCCCCCCCCCCCC | 26.37 | 23401153 | |
178 | Phosphorylation | HMIRDIQTLLSRMET HHHHHHHHHHHHHHH | 29.96 | 21406692 | |
181 | Phosphorylation | RDIQTLLSRMETLPY HHHHHHHHHHHHCCC | 32.47 | 21406692 | |
181 (in isoform 2) | Phosphorylation | - | 32.47 | 22817900 | |
181 (in isoform 3) | Phosphorylation | - | 32.47 | 22817900 | |
181 (in isoform 4) | Phosphorylation | - | 32.47 | 22817900 | |
181 (in isoform 5) | Phosphorylation | - | 32.47 | 22817900 | |
185 | Phosphorylation | TLLSRMETLPYLQCR HHHHHHHHCCCCCCC | 24.56 | 22210691 | |
200 | Phosphorylation | GGPQPQHSQPPPQPP CCCCCCCCCCCCCCC | 38.85 | 25850435 | |
210 | Phosphorylation | PPQPPAVTPEPVALS CCCCCCCCCCCEECC | 24.84 | 25850435 | |
217 | Phosphorylation | TPEPVALSSQTSEPV CCCCEECCCCCCCCC | 15.63 | 25850435 | |
218 | Phosphorylation | PEPVALSSQTSEPVE CCCEECCCCCCCCCC | 38.02 | 17478428 | |
220 | Phosphorylation | PVALSSQTSEPVESE CEECCCCCCCCCCCC | 36.68 | 25850435 | |
221 | Phosphorylation | VALSSQTSEPVESEA EECCCCCCCCCCCCC | 32.06 | 25850435 | |
251 | Phosphorylation | PAQNPELTPGPAPAG CCCCCCCCCCCCCCC | 25.25 | 29496963 | |
260 | O-linked_Glycosylation | GPAPAGPTPAPETNA CCCCCCCCCCCCCCC | 31.03 | OGP | |
260 | Phosphorylation | GPAPAGPTPAPETNA CCCCCCCCCCCCCCC | 31.03 | 25332170 | |
265 | Phosphorylation | GPTPAPETNAPNHPS CCCCCCCCCCCCCCC | 35.30 | 25332170 | |
329 | Phosphorylation | LINLVGESLRLLGNT HHHHHHHHHHHHCCC | 16.92 | 21601212 | |
341 | Phosphorylation | GNTFVALSDLRCNLA CCCEEEHHHCCCCCC | 25.51 | 24719451 | |
344 | Methylation | FVALSDLRCNLACTP EEEHHHCCCCCCCCC | 16.56 | - | |
350 | Phosphorylation | LRCNLACTPPRHLHV CCCCCCCCCCCEEEE | 30.62 | 22617229 | |
508 | Phosphorylation | RVVIARPTPPQARPS EEEEECCCCCCCCCC | 41.89 | 26270265 | |
697 | Phosphorylation | GLGLESLSPEFFTSV CCCHHHCCHHHHHHH | 31.49 | - | |
722 | Phosphorylation | SLGARAGSSESIAAF HHHHCCCCHHHHHHH | 29.92 | 25693802 | |
723 | Phosphorylation | LGARAGSSESIAAFI HHHCCCCHHHHHHHH | 34.15 | 25693802 | |
725 | Phosphorylation | ARAGSSESIAAFIQR HCCCCHHHHHHHHHH | 21.34 | 25693802 | |
806 | Sulfoxidation | PTPSNIRMATHTLIT CCHHHHHHHHHHHHH | 4.46 | 28183972 | |
818 | Phosphorylation | LITGLEEYVRESFSL HHHCHHHHHHHHCCE | 8.74 | 22817900 | |
832 (in isoform 4) | Phosphorylation | - | 6.42 | 23663014 | |
915 | Phosphorylation | PSLVSWLTTMMGLRL HHHHHHHHHHHHHHH | 13.34 | - | |
955 | Sulfoxidation | QPLPEEPMEVQGAER CCCCCCCCCCCCCCC | 9.97 | 30846556 | |
964 | Phosphorylation | VQGAERASPEPQREN CCCCCCCCCCCCCCC | 35.70 | 29255136 | |
973 | Phosphorylation | EPQRENASPAPGTTA CCCCCCCCCCCCCCH | 32.93 | 19664994 | |
978 | Phosphorylation | NASPAPGTTAEEAMS CCCCCCCCCHHHHHH | 23.05 | 22167270 | |
979 | Phosphorylation | ASPAPGTTAEEAMSR CCCCCCCCHHHHHHC | 37.68 | 22167270 | |
984 | Sulfoxidation | GTTAEEAMSRGPPPA CCCHHHHHHCCCCCC | 2.95 | 21406390 | |
985 | Phosphorylation | TTAEEAMSRGPPPAP CCHHHHHHCCCCCCC | 40.93 | 30278072 | |
996 | Phosphorylation | PPAPEGGSRDEQDGA CCCCCCCCCCCCCCC | 47.63 | 28176443 | |
1027 (in isoform 2) | Ubiquitination | - | 41.63 | 21890473 | |
1033 | Acetylation | IQSQRKVKPQPPLSD HHHCCCCCCCCCCCH | 40.76 | 26051181 | |
1033 | Ubiquitination | IQSQRKVKPQPPLSD HHHCCCCCCCCCCCH | 40.76 | 21906983 | |
1033 (in isoform 1) | Ubiquitination | - | 40.76 | 21890473 | |
1039 | Phosphorylation | VKPQPPLSDAYLSGM CCCCCCCCHHHHCCC | 26.43 | 19060867 | |
1042 | Phosphorylation | QPPLSDAYLSGMPAK CCCCCHHHHCCCCCC | 13.34 | 19060867 | |
1043 | Ubiquitination | PPLSDAYLSGMPAKR CCCCHHHHCCCCCCC | 3.70 | 21890473 | |
1043 (in isoform 2) | Ubiquitination | - | 3.70 | 21890473 | |
1044 | Phosphorylation | PLSDAYLSGMPAKRR CCCHHHHCCCCCCCC | 21.99 | 28555341 | |
1046 | Ubiquitination | SDAYLSGMPAKRRKT CHHHHCCCCCCCCCC | 2.34 | 21890473 | |
1046 (in isoform 2) | Ubiquitination | - | 2.34 | 21890473 | |
1049 | Ubiquitination | YLSGMPAKRRKTMQG HHCCCCCCCCCCCCC | 47.03 | 21890473 | |
1049 | Acetylation | YLSGMPAKRRKTMQG HHCCCCCCCCCCCCC | 47.03 | 25953088 | |
1049 | Ubiquitination | YLSGMPAKRRKTMQG HHCCCCCCCCCCCCC | 47.03 | 21890473 | |
1049 (in isoform 1) | Ubiquitination | - | 47.03 | 21890473 | |
1049 (in isoform 5) | Phosphorylation | - | 47.03 | 27251275 | |
1052 | Ubiquitination | GMPAKRRKTMQGEGP CCCCCCCCCCCCCCH | 53.00 | 21890473 | |
1052 | Ubiquitination | GMPAKRRKTMQGEGP CCCCCCCCCCCCCCH | 53.00 | 21890473 | |
1052 (in isoform 1) | Ubiquitination | - | 53.00 | 21890473 | |
1053 | Phosphorylation | MPAKRRKTMQGEGPQ CCCCCCCCCCCCCHH | 16.96 | 25159151 | |
1063 (in isoform 3) | Ubiquitination | - | 6.22 | 21890473 | |
1064 | Phosphorylation | EGPQLLLSEAVSRAA CCHHHHHHHHHHHHH | 24.39 | - | |
1072 | Ubiquitination | EAVSRAAKAAGARPL HHHHHHHHHCCCCCC | 37.47 | - | |
1079 (in isoform 3) | Ubiquitination | - | 6.54 | 21890473 | |
1080 | Phosphorylation | AAGARPLTSPESLSR HCCCCCCCCHHHHHH | 44.94 | 23401153 | |
1081 | Phosphorylation | AGARPLTSPESLSRD CCCCCCCCHHHHHHC | 34.06 | 19664994 | |
1082 (in isoform 3) | Ubiquitination | - | 29.93 | 21890473 | |
1084 | Phosphorylation | RPLTSPESLSRDLEA CCCCCHHHHHHCCCC | 34.72 | 23927012 | |
1086 | Phosphorylation | LTSPESLSRDLEAPE CCCHHHHHHCCCCHH | 32.78 | 23927012 | |
1104 | Phosphorylation | SYRQQLRSDIQKRLQ HHHHHHHHHHHHHHH | 47.89 | 27251275 | |
1116 | Phosphorylation | RLQEDPNYSPQRFPN HHHHCCCCCCCCCCC | 27.41 | 21945579 | |
1117 | Phosphorylation | LQEDPNYSPQRFPNA HHHCCCCCCCCCCCH | 22.61 | 19664994 | |
1146 (in isoform 3) | Phosphorylation | - | 27642862 |
Modified Location | Modified Residue | Modification | Function | Reference | ||
---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of BAG6_HUMAN !! |
* Distance = the distance between SAP position and PTM sites.
Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of BAG6_HUMAN !! |
Kegg Disease | ||||||
---|---|---|---|---|---|---|
There are no disease associations of PTM sites. | ||||||
OMIM Disease | ||||||
There are no disease associations of PTM sites. | ||||||
Kegg Drug | ||||||
There are no disease associations of PTM sites. | ||||||
DrugBank | ||||||
There are no disease associations of PTM sites. |
loading...
Acetylation | |
Reference | PubMed |
"Lys-N and trypsin cover complementary parts of the phosphoproteome ina refined SCX-based approach."; Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,Mohammed S.; Anal. Chem. 81:4493-4501(2009). Cited for: ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, PHOSPHORYLATION [LARGESCALE ANALYSIS] AT THR-108; SER-113; THR-350; SER-973 AND SER-1117,AND MASS SPECTROMETRY. | |
Phosphorylation | |
Reference | PubMed |
"Quantitative phosphoproteomic analysis of T cell receptor signalingreveals system-wide modulation of protein-protein interactions."; Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,Rodionov V., Han D.K.; Sci. Signal. 2:RA46-RA46(2009). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-964 AND SER-973, ANDMASS SPECTROMETRY. | |
"Lys-N and trypsin cover complementary parts of the phosphoproteome ina refined SCX-based approach."; Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,Mohammed S.; Anal. Chem. 81:4493-4501(2009). Cited for: ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, PHOSPHORYLATION [LARGESCALE ANALYSIS] AT THR-108; SER-113; THR-350; SER-973 AND SER-1117,AND MASS SPECTROMETRY. | |
"A quantitative atlas of mitotic phosphorylation."; Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,Elledge S.J., Gygi S.P.; Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-113; THR-350; SER-964;SER-973; SER-1081 AND SER-1117, AND MASS SPECTROMETRY. | |
"Phosphoproteome of resting human platelets."; Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,Schuetz C., Walter U., Gambaryan S., Sickmann A.; J. Proteome Res. 7:526-534(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-973, AND MASSSPECTROMETRY. | |
"Improved titanium dioxide enrichment of phosphopeptides from HeLacells and high confident phosphopeptide identification by cross-validation of MS/MS and MS/MS/MS spectra."; Yu L.-R., Zhu Z., Chan K.C., Issaq H.J., Dimitrov D.S., Veenstra T.D.; J. Proteome Res. 6:4150-4162(2007). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-113, AND MASSSPECTROMETRY. | |
"A probability-based approach for high-throughput proteinphosphorylation analysis and site localization."; Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.; Nat. Biotechnol. 24:1285-1292(2006). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1117, AND MASSSPECTROMETRY. | |
"Global, in vivo, and site-specific phosphorylation dynamics insignaling networks."; Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,Mann M.; Cell 127:635-648(2006). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-964; SER-1039 ANDTYR-1042, AND MASS SPECTROMETRY. | |
"Large-scale characterization of HeLa cell nuclear phosphoproteins."; Beausoleil S.A., Jedrychowski M., Schwartz D., Elias J.E., Villen J.,Li J., Cohn M.A., Cantley L.C., Gygi S.P.; Proc. Natl. Acad. Sci. U.S.A. 101:12130-12135(2004). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-964; SER-973 ANDSER-1117, AND MASS SPECTROMETRY. |